Article

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

2021-12-03

Abstract excerpt

Abstract Loss-of-function mutations in the RB1 tumour suppressor are key drivers in cancer, including osteosarcoma. RB1 loss-of-function compromises genome-maintenance and hence could yield vulnerability to therapeutics targeting such processes. Here we demonstrate selective hypersensitivity to clinically-approved inhibitors of Poly-ADP-Polymerase1,2 inhibitors (PARPi) in RB1-defective cancer cells, including an e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4024a88e-014b-5ad7-9493-66d2492b1400
DOI: 10.1038/s41467-021-27291-8

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaDOI 10.1038/s41467-021-27291-8Read

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read

Therapeutic vulnerability to PARP1/2 inhibition in <i>RB1</i> -mutant osteosarcomaSemantic proximity Read

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.Semantic proximity Read

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeuticsSemantic proximity Read

Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated CancerSemantic proximity Read

PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistanceSemantic proximity Read

‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancerSemantic proximity Read

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian CancerSemantic proximity Read

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant CancersSemantic proximity Read

Insights into the Possible Molecular Mechanisms of Resistance to PARP InhibitorsSemantic proximity Read

Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcomaSemantic proximity Read